# Menstrual Blood Stem Cells in Severe Covid-19

> **NCT05019287** · PHASE1,PHASE2 · COMPLETED · sponsor: **Avicenna Research Institute** · enrollment: 29 (actual)

## Conditions studied

- Covid19
- Cytokine Storm

## Interventions

- **BIOLOGICAL:** Allogeneic human menstrual blood stem cells secretome
- **OTHER:** Intravenous saline injection

## Key facts

- **NCT ID:** NCT05019287
- **Lead sponsor:** Avicenna Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-17
- **Primary completion:** 2021-05-21
- **Final completion:** 2021-06-09
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2021-09-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05019287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05019287, "Menstrual Blood Stem Cells in Severe Covid-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05019287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*